Discovery and characterization of an immunosuppressive tumor microenvironmental (TME) niche in classic Hodgkin lymphoma
Margaret Shipp
MDDana-Farber Cancer Institute
Project Term: July 1, 2020 - June 30, 2023
Dr. Shipp and her colleague, Scott J. Rodig, MD, Ph.D., are mapping the immune microenvironment in classical Hodgkin lymphoma.
Immune checkpoint blockade therapy targeting PD-1/PD-L1 has transformed the treatment and prognosis for many cancer patients. Notably, it has seen successes in managing relapsed or refractory classical Hodgkin’s lymphoma, which expresses high levels of PD-L1. However, despite initial response to such therapy, most patients will eventually relapse. Thus, despite high levels of PD-L1 expression, there is an incomplete understanding of how these lymphomas come to resist PD-1/PD-L1 checkpoint blockade, mostly likely the result of multiple pathways capable of promoting immune evasion. To address these questions, Margaret Shipp and her collaborators are using a novel technique to probe the immune microenvironment in Hodgkin’s lymphoma. They are employing multiplex ion beam imaging time of flight mass spectrometry (MIBI-TOF), which uses antibodies conjugated to rare metal isotopes to understand the spatial organization of immune and tumor markers. MIBI-TOF allows for more precision than fluorescent markers, which can be difficult to deconvolute because of spectral overlap. They are harnessing this unprecedented spatial resolution to observe the immune response in the native tumor microenvironment in samples from patients who have been treated with induction therapy or PD-1 blockade. Finally, they will further characterize cells in the tumor microenvironment by single cell RNA sequencing, which when combined with MIBI-TOF data, will identify novel vulnerabilities of these cells and other rational therapeutic targets. These studies will provide insight into the complex immune evasion strategies used by tumors and set the foundation for novel therapies to augment treatments.
This Discovery award is sponsored through a partnership between LLS, the Mark Foundation for Cancer Research and The Paul G. Allen Frontiers Group.